This position may no longer be available
This job was last seen 1 week ago. The listing may have been removed by the employer.
Lead the EU Regulatory Affairs function for Olema Oncology, driving regulatory strategies and compliance for oncology programs.
Posted by employer 3 months ago
First seen on Joblaze 2 months ago
Last verified on the company career page 1 week ago
Skills & Technologies
Requirements
Not disclosed in this posting: compensation, visa sponsorship.
Benefits
Joblaze summary
The Senior Director of EU Regulatory Strategy at Olema Oncology leads the regulatory affairs function for the company's European subsidiary, focusing on strategic oversight of regulatory activities related to oncology programs. This role requires extensive experience in European regulatory frameworks, particularly in managing Clinical Trial Applications and Marketing Authorization Applications, alongside strong leadership and communication skills. Ideal candidates will have a robust background in regulatory affairs within the biotechnology or pharmaceutical sectors, particularly in oncology. Olema is in a transformative phase, aiming to establish itself as a fully integrated oncology company
Joblaze insights
Quick facts
From the original posting
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity.
Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP-3136 in combination with Bayer’s darolutamide in metastatic castration-resistant prostate cancer by the end of this year.
Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self-starters who bring consistency in our quest for the extraordinary every single day.
If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.
About the Role >>> Senior Director, EU Regulatory Affairs
Reporting to Senior Vice President, Regulatory Affairs, the Senior Director, EU Regulatory Affairs is responsible for leading the Regulatory Affairs function for Olema International, the Company's European subsidiary based in Ireland. Serving as the EU Authorized Representative, this individual provides strategic leadership for European regulatory activities supporting Olema's oncology programs and future commercialization efforts. The role is accountable for developing and executing EU regulatory strategies, leading interactions with the European Medicines Agency (EMA) and National Competent Authorities (NCAs), overseeing Clinical Trial Applications (CTAs) and CTIS activities, directing the submission and lifecycle management of the European Marketing Authorization Application (MAA), and ensuring ongoing regulatory compliance across the European Union.
This role is based out of our Dublin, Ireland office and will require 15% - 20% International travel.
Your work will primarily encompass:
Ideal Candidate Profile >>> European Union Regulatory Representative
Education and Required Skills
#LI-MK1
Important Information >>>
Standard company text repeated across Olema Oncology's postings is omitted here.